Get started
Author

Kathryn Kersey

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
2020 · Stephen A. Harrison, Vincent Wai-Sun Wong, et al. · Journal of Hepatology · 493
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
2019 · Quentin M. Anstee, Eric J. Lawitz, et al. · Hepatology · 276
The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection
2016 · William F. Balistreri, Karen F. Murray, et al. · Hepatology · 191
PDF
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
2014 · Peter J. Ruane, Dani Ain, et al. · Journal of Hepatology · 167
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
2010 · J E Lancet, I Gojo, et al. · Leukemia · 155
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4
2015 · Wahid Doss, Gamal Shiha, et al. · Journal of Hepatology · 145
A preliminary study of aquatic insect communities and leaf decomposition in acid streams near Dorset, Ontario
1985 · Rosemary J. Mackay, Kathryn E. Kersey · Hydrobiologia · 120
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
2020 · Zobair M. Younossi, Quentin M. Anstee, et al. · Gastroenterology · 118
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection
2016 · Armand Abergel, Sophie Metivier, et al. · Hepatology · 115
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study
2010 · M. Goldberg, Y.‐P. Li, et al. · Alimentary Pharmacology & Therapeutics · 113
Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11
2018 · Karen F. Murray, William F. Balistreri, et al. · Hepatology · 109
Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection
2017 · Stefan Wirth, Philip Rosenthal, et al. · Hepatology · 104
PDF
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
2016 · Armand Abergel, Tarik Asselah, et al. · The Lancet Infectious Diseases · 100
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
2019 · Zobair M. Younossi, Maria Stepanova, et al. · Clinical Gastroenterology and Hepatology · 87
PDF
Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
2008 · S. Modi, S. Sugarman, et al. · Journal of Clinical Oncology · 62
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
2020 · Zobair M Younossi, Vincent Wai‐Sun Wong, et al. · Hepatology Communications · 52
PDF
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
2018 · Gamal Shiha, Gamal Esmat, et al. · Gut · 51
Sex Differences of Brain Serotonin Synthesis in Patients with Irritable Bowel Syndrome Using α-[11C]methyl-L-tryptophan, Positron Emission Tomography and Statistical Parametric Mapping
2003 · Akio Nakai, Yoshikata Kumakura, et al. · Canadian Journal of Gastroenterology · 49
PDF
The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties
2011 · David T. Beattie, Scott R. Armstrong, et al. · Frontiers in Pharmacology · 43
PDF
O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection
2015 · A. Abergel, V. Loustaud-Ratti, et al. · Journal of Hepatology · 36
An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954
2012 · D.T. Beattie, D.L. Higgins, et al. · Vascular Pharmacology · 34
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
2022 · Vincent Wai-Sun Wong, Won Young Tak, et al. · Clinical Gastroenterology and Hepatology · 31
PDF
An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d ]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing
2008 · George R. Tonn, Simon G. Wong, et al. · Drug Metabolism and Disposition · 31
Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.
2007 · Paul G. Richardson, Asher Chanan-Khan, et al. · Blood · 30
Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors
2004 · K. M. Koch, B. W. Corrigan, et al. · Alimentary Pharmacology & Therapeutics · 28
Works count: 86
Citation count: 3,132
H-index: 27
I10-index: 45
Year
Topic
Type